Literature DB >> 26687678

Ubiquitin-Dependent Turnover of MYC Antagonizes MYC/PAF1C Complex Accumulation to Drive Transcriptional Elongation.

Laura A Jaenicke1, Björn von Eyss1, Anne Carstensen1, Elmar Wolf1, Wenshan Xu2, Ann Katrin Greifenberg3, Matthias Geyer3, Martin Eilers4, Nikita Popov5.   

Abstract

MYC is an unstable protein, and its turnover is controlled by the ubiquitin system. Ubiquitination enhances MYC-dependent transactivation, but the underlying mechanism remains unresolved. Here we show that MYC proteasomal turnover is dispensable for loading of RNA polymerase II (RNAPII). In contrast, MYC turnover is essential for recruitment of TRRAP, histone acetylation, and binding of BRD4 and P-TEFb to target promoters, leading to phosphorylation of RNAPII and transcriptional elongation. In the absence of histone acetylation and P-TEFb recruitment, MYC associates with the PAF1 complex (PAF1C) through a conserved domain in the MYC amino terminus ("MYC box I"). Depletion of the PAF1C subunit CDC73 enhances expression of MYC target genes, suggesting that the MYC/PAF1C complex can inhibit transcription. Because several ubiquitin ligases bind to MYC via the same domain ("MYC box II") that interacts with TRRAP, we propose that degradation of MYC limits the accumulation of MYC/PAF1C complexes during transcriptional activation.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  MYC; PAF1C; RNA polymerase; proteasomal degradation; transcriptional elongation; ubiquitin

Mesh:

Substances:

Year:  2015        PMID: 26687678     DOI: 10.1016/j.molcel.2015.11.007

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   17.970


  45 in total

1.  TEAD activity is restrained by MYC and stratifies human breast cancer subtypes.

Authors:  Dana Elster; Laura A Jaenicke; Martin Eilers; Björn von Eyss
Journal:  Cell Cycle       Date:  2016-07-19       Impact factor: 4.534

Review 2.  PD2/PAF1 at the Crossroads of the Cancer Network.

Authors:  Saswati Karmakar; Parama Dey; Arokia P Vaz; Sukesh R Bhaumik; Moorthy P Ponnusamy; Surinder K Batra
Journal:  Cancer Res       Date:  2018-01-08       Impact factor: 12.701

3.  The MYC mRNA 3'-UTR couples RNA polymerase II function to glutamine and ribonucleotide levels.

Authors:  Francesca R Dejure; Nadine Royla; Steffi Herold; Jacqueline Kalb; Susanne Walz; Carsten P Ade; Guido Mastrobuoni; Jens T Vanselow; Andreas Schlosser; Elmar Wolf; Stefan Kempa; Martin Eilers
Journal:  EMBO J       Date:  2017-04-13       Impact factor: 11.598

Review 4.  Family matters: How MYC family oncogenes impact small cell lung cancer.

Authors:  Johannes Brägelmann; Stefanie Böhm; Matthew R Guthrie; Gurkan Mollaoglu; Trudy G Oliver; Martin L Sos
Journal:  Cell Cycle       Date:  2017-07-24       Impact factor: 4.534

Review 5.  Target gene-independent functions of MYC oncoproteins.

Authors:  Apoorva Baluapuri; Elmar Wolf; Martin Eilers
Journal:  Nat Rev Mol Cell Biol       Date:  2020-02-18       Impact factor: 94.444

6.  Recruitment of BRCA1 limits MYCN-driven accumulation of stalled RNA polymerase.

Authors:  Steffi Herold; Jacqueline Kalb; Gabriele Büchel; Carsten P Ade; Apoorva Baluapuri; Jiajia Xu; Jan Koster; Daniel Solvie; Anne Carstensen; Christina Klotz; Sabrina Rodewald; Christina Schülein-Völk; Matthias Dobbelstein; Elmar Wolf; Jan Molenaar; Rogier Versteeg; Susanne Walz; Martin Eilers
Journal:  Nature       Date:  2019-03-20       Impact factor: 49.962

7.  Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacologic Targeting of the P-TEFb Complex.

Authors:  Jon S Zawistowski; Samantha M Bevill; Daniel R Goulet; Timothy J Stuhlmiller; Adriana S Beltran; Jose F Olivares-Quintero; Darshan Singh; Noah Sciaky; Joel S Parker; Naim U Rashid; Xin Chen; James S Duncan; Martin C Whittle; Steven P Angus; Sara Hanna Velarde; Brian T Golitz; Xiaping He; Charlene Santos; David B Darr; Kristalyn Gallagher; Lee M Graves; Charles M Perou; Lisa A Carey; H Shelton Earp; Gary L Johnson
Journal:  Cancer Discov       Date:  2017-01-20       Impact factor: 39.397

8.  Enhancer remodeling regulates epigenetic adaptation and resistance to MEK1/2 inhibition in triple-negative breast cancer.

Authors:  Samantha M Bevill; Jon S Zawistowski; Gary L Johnson
Journal:  Mol Cell Oncol       Date:  2017-03-31

9.  OmoMYC blunts promoter invasion by oncogenic MYC to inhibit gene expression characteristic of MYC-dependent tumors.

Authors:  L A Jung; A Gebhardt; W Koelmel; C P Ade; S Walz; J Kuper; B von Eyss; S Letschert; C Redel; L d'Artista; A Biankin; L Zender; M Sauer; E Wolf; G Evan; C Kisker; M Eilers
Journal:  Oncogene       Date:  2016-10-17       Impact factor: 9.867

10.  Reduced chromatin binding of MYC is a key effect of HDAC inhibition in MYC amplified medulloblastoma.

Authors:  Jonas Ecker; Venu Thatikonda; Gianluca Sigismondo; Florian Selt; Gintvile Valinciute; Ina Oehme; Carina Müller; Juliane L Buhl; Johannes Ridinger; Diren Usta; Nan Qin; Cornelis M van Tilburg; Christel Herold-Mende; Marc Remke; Felix Sahm; Frank Westermann; Marcel Kool; Robert J Wechsler-Reya; Lukas Chavez; Jeroen Krijgsveld; Natalie Jäger; Stefan M Pfister; Olaf Witt; Till Milde
Journal:  Neuro Oncol       Date:  2021-02-25       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.